Paul Ridker, MD, MPH
October 3rd, 2012
CRP and Cholesterol Emerge as Equally Strong Predictors of Cardiovascular Risk
Paul Ridker, MD, MPH
Paul Ridker discusses findings from the Emerging Risk Factors Collaboration showing that C-reactive protein provides incremental risk information comparable to that of total cholesterol and HDL cholesterol.
August 30th, 2012
Low-Dose Methotrexate to Prevent Recurrent MI and Stroke?
Paul Ridker, MD, MPH
Paul Ridker discusses the Cardiovascular Inflammation Reduction Trial, which will formally test the inflammatory hypothesis.
January 28th, 2011
Does CRP Level Modify the Benefit of Statins? Paul Ridker Reacts to New Data
Paul Ridker, MD, MPH
CardioExchange welcomes Paul M. Ridker, a leading researcher on the value of C-reactive protein (CRP) concentration as a prognostic marker of cardiovascular risk, to respond to the latest data on CRP and statin therapy from the Heart Protection Study (HPS). The New HPS Findings on CRP: The HPS investigators sought to determine whether statin therapy might […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?